Page 3 - Technologies Munich News Today

New manufacturing plant in Neufahrn near Munich increases ITMs production capacity tenfoldCeremonial opening by Minister of State, Dr. Florian Herrmann, Head of the Bavarian State Chancellery

ITM Isotope Technologies Munich is a leader in Targeted Radionuclide Therapy, an emerging class of cancer treatment.

On May 24, 2023, it was reported in The Gleaner newspaper that Jamaican Canadian billionaire and executive chair of the National Commercial Bank (NCB,) Michael Lee-Chin, will take a three-month leave of absence to “focus on pressing business and personal matters.”

Enhancement of ITM's development and manufacturing activities strengthens ITM's position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) Garching / Munich, April 27, 2023 - ITM Isotope

Enhancement of ITM’s development and manufacturing activities strengthens ITM’s position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) ...

/PRNewswire/ -- DelveInsights Nuclear Medicine Market Insights report provides the current and forecast market analysis, individual leading nuclear medicine...

The nuclear medicine market is expanding rapidly due to the rising prevalence of cancer, cardiovascular disease, and other chronic diseases caused by an inactive lifestyle. Furthermore, the

Investegate announcements from ITM Isotope Technologies Munic, ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference

Garching / Munich, March 16, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the...

Garching / Munich, March 16, 2023 - ITM Isotope Technologies Munich SE) in a poster presentation at the 20th Annual European Neuroendocrine Tumor Society(n.c.a. 177Lu-edotreotide) compared to standard